Requiring an amyloid‐β1‐42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (Q34162069)
Jump to navigation
Jump to search
scientific article published on September 1, 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Requiring an amyloid‐β1‐42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials |
scientific article published on September 1, 2010 |
Statements
1 reference
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (English)
1 reference
Requiring an amyloid‐β1‐42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (English)
Alzheimer’s Disease Neuroimaging Initiative
1 reference
Richard E. Kennedy
Lon S. Schneider
Alzheimer’s Disease Neuroimaging Initiative
1 September 2010
1 reference
1 reference
367-377
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference